Bioinformatics identifies key genes and potential drugs for energy metabolism disorders in heart failure with dilated cardiomyopathy
Conclusion: The study findings highlight the crucial role of myocardial energy metabolism in the progression of Dilated Cardiomyopathy. Notably, Benzoylaconine emerges as a potential candidate for treating Dilated Cardiomyopathy, potentially exerting its therapeutic effects by targeted modulation of myocardial energy metabolism through NRK and NT5.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiomyopathy | Databases & Libraries | Dilated Cardiomyopathy | Drugs & Pharmacology | Genetics | Heart | Heart Failure | Molecular Biology | Study